Testing Of New Drug For Patients With Neuroendocrine Tumors
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that the drug was effective and well tolerated in controlling patient symptoms.
The study results are reported in a recent issue of Endocrine-Related Cancer, a publication of the Society for Endocrinology.
“Neuroendocrine tumors are often asymptomatic and, by the time of diagnosis, have frequently metastasized, usually to the liver,” said the study’s corresponding author, Larry K. Kvols, M.D., a senior member at Moffitt and section head of neuroendocrine oncology. “Surgery is essential in managing metastatic NET and can be curative for early disease, but the majority of patients need further treatment.”
According to Kvols, octreotide and lanreotide, drugs that mimic natural somatostatin, have been “the mainstay” for symptom management of neuroendocrine tumors. However, many patients eventually fail to respond to this treatment and have poor prognoses.
“Pasireotide is a novel multireceptor-targeted somatostatin analogue that binds to four of the five known somatostatin receptor subtypes,” said Kvols, whose research is in experimental therapies for neuroendocrine cancer. “Because of its binding ability, it may offer symptom reduction for patients who have eventually failed to respond to traditional therapy.”
The multicenter clinical trial, conducted at sites in the United States and Europe, enrolled 89 patients and evaluated 44 for efficacy and 45 for tolerability. Pasireotide “effectively controlled symptoms.” Evaluation of tumor response in 23 patients showed 13 with stable disease and 10 with progressive disease. The drug was “effective and well-tolerated” and adverse events, most commonly gastrointestinal, were “mild or moderately severe.”
The study was funded in part through funding by Novaratis Pharmaceuticals.
A Phase III study evaluating pasireotide versus octreotide is ongoing for patients with advanced NET whose disease-related symptoms have been inadequately controlled.
Related Posts
Your own genome can make your more susceptible to TB infection and recurrent TB
Tuberclosis(TB) being the infectious disease is communicated almost exclusively by coughed aerosols carrying pathogens of Mycobacterium tuberclosis (Mtb). As reported by World Health Organization (WHO) it causes disease in 9.6 millions people each year and ranks with human immunodeficiency virus (HIV) as a leading cause of disease. A well timed diagnosis and appropriate treatment can […]
Read More »
Testing Of New Drug For Patients With Neuroendocrine Tumors
A researcher at Moffitt Cancer Center and his international team of colleagues have reported study results on a novel multireceptor-targeted somatostatin analogue called pasireotide (SOM230) manufactured by Novartis Pharma AG. The Phase II, open-label, multicenter study in patients with advanced neuroendocrine tumors (NET) whose symptoms were no longer responsive to octreotide LAR therapy found that […]
Read More »
Greater Incidence Of Babies With Retinoblastoma In US-Born Latinas
In a large epidemiologic study, researchers at UCLA’s Jonsson Cancer Center found that the children of U.S.-born Latina women are at higher risk of having retinoblastoma, a malignant tumor of the retina which typically occurs in children under six. The study, which focused on babies born in California, also found that offspring of older fathers […]
Read More »
Diesel Soot Re-Classified As Carcinogenic, Causing Lung Cancer
Since June 2012, it is official: The World Health Organisation (WHO) has classified diesel soot as a lung carcinogen. Artur Braun, a physicist at Empa and an X-ray spectroscopy expert, has made crucial contributions to analyzing the structure and composition of soot particles. Soot particles are dangerous – there is nothing new in this knowledge. […]
Read More »
Grapefruit Juice Helps Anti-Cancer Drug Work Better
A new clinical trial published in the August edition of Clinical Cancer Research has revealed that cancer patients who drink one glass of grapefruit juice per day achieve the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself. It could also help […]
Read More »
Disease Management Programme Module On Heart Failure: Current Guidelines Indicate Some Need For Revision
On 14 February 2012, the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with heart failure. The aim of the report is to identify those recommendations from current guidelines of high methodological quality that may be […]
Read More »
SPECT/CT Imaging Agent Solves The Problem Of Difficult To Diagnose Cases Of Infectious Endocarditis
When combined with standard diagnostic tests, functional imaging procedures have been shown to reduce the rate of misdiagnosed cases of infectious endocarditis. According to new research published in the August issue of The Journal of Nuclear Medicine, single photon emission computed tomography (SPECT)/computed tomography (CT) with 99mTc-hexamethylpropleneamine oxime-labeled white blood cells (99mTc-HMPAO-WBC) can improve the […]
Read More »
Molecule Discovered That Converts Stem Cells Into Heart Cells
For years, scientists have been looking for a good source of heart cells that can be used to study cardiac function in the lab, or perhaps even to replace diseased or damaged tissue in heart disease patients. To do this, many are looking to stem cells. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham), the Human […]
Read More »
The Genetic Map Of The Jewish Diasporas Defined By New Genetic Study
A new genetic analysis focusing on Jews from North Africa has provided an overall genetic map of the Jewish Diasporas. The findings support the historical record of Middle Eastern Jews settling in North Africa during Classical Antiquity, proselytizing and marrying local populations, and, in the process, forming distinct populations that stayed largely intact for more […]
Read More »
Investing In Quality Of Care For Diabetic Patients Reduces Costs
University of Minnesota School of Public Health researchers have found that medical group practices can reduce costs for patients with diabetes by investing in improved quality of care. In the study, which appears in the August issue of Health Affairs, University of Minnesota researchers analyzed 234 medical group practices providing care for more than 133,000 […]
Read More »